146 related articles for article (PubMed ID: 28222307)
1. Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
Rovers KP; Simkens GA; Vissers PA; Lemmens VE; Verwaal VJ; Bremers AJ; Wiezer MJ; Burger JW; Hemmer PH; Boot H; van Grevenstein WM; Meijerink WJ; Aalbers AG; Punt CJ; Tanis PJ; de Hingh IH;
Eur J Cancer; 2017 Apr; 75():132-140. PubMed ID: 28222307
[TBL] [Abstract][Full Text] [Related]
2. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study.
van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; Boerma D; van Grevenstein WMU; Hemmer PHJ; Kok NFM; Madsen EVE; de Reuver P; Tuynman JB; van Erning FN; de Hingh IHJT
Ann Surg Oncol; 2024 Jun; 31(6):3758-3768. PubMed ID: 38453767
[TBL] [Abstract][Full Text] [Related]
3. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
4. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
6. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
7. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium.
Sluiter NR; van der Bilt JD; Croll DMR; Vriens MR; de Hingh IHJT; Hemmer P; Aalbers AGJ; Bremers AJA; Ceelen W; D'Hoore A; Schoonmade LJ; Coupé V; Verheul H; Kazemier G; Tuynman JB;
Clin Colorectal Cancer; 2020 Sep; 19(3):e87-e99. PubMed ID: 32651131
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
[TBL] [Abstract][Full Text] [Related]
9. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
11. Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon.
Legué LM; Simkens GA; Creemers GM; Lemmens VEPP; de Hingh IHJT
Eur J Cancer; 2017 Dec; 87():84-91. PubMed ID: 29132061
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study.
Simkens GA; van Oudheusden TR; Braam HJ; Wiezer MJ; Nienhuijs SW; Rutten HJ; van Ramshorst B; de Hingh IH
J Surg Oncol; 2016 Apr; 113(5):548-53. PubMed ID: 27110701
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
15. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
16. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit?
Rivard JD; McConnell YJ; Temple WJ; Mack LA
J Surg Oncol; 2014 Feb; 109(2):104-9. PubMed ID: 24449172
[TBL] [Abstract][Full Text] [Related]
17. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
Saxena A; Valle SJ; Liauw W; Morris DL
Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
20. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: Results of a population-based study.
Razenberg LG; Lemmens VE; Verwaal VJ; Punt CJ; Tanis PJ; Creemers GJ; de Hingh IH
Eur J Cancer; 2016 Sep; 65():113-20. PubMed ID: 27497343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
